Ischemic and Inflammatory Ocular Adverse Events Following Different Types of Vaccination for COVID-19 and Their Incidence Analysis

Overview

Journal Korean J Ophthalmol

Specialty Ophthalmology

Date 2024 Apr 15

PMID 38622066

Authors

Eoi Jong Seo

Moon Sun Jung

Kibum Lee

Kyung Tae Kim

Mi Young Choi

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the ocular adverse event (OAE) and the incidence rate that can occur after the COVID-19 vaccination.

Methods: Patients who visited with an ophthalmologic diagnosis within a month of COVID-19 vaccination were retrospectively analyzed. OAEs were categorized as ischemia and inflammation by their presumed pathogenesis and were compared by types of vaccine: messenger RNA (mRNA) and viral vector vaccine. The crude incidence rate was calculated using data from the Korea Disease Control and Prevention Agency.

Results: Twenty-four patients with OAEs after COVID-19 vaccination were reviewed: 10 patients after mRNA and 14 after viral vector vaccine. Retinal vein occlusion (nine patients) and paralytic strabismus (four patients) were the leading diagnoses. Ischemic OAE was likely to occur after viral vector vaccines, while inflammatory OAE was closely related to mRNA vaccine (p = 0.017). The overall incidence rate of OAE was 5.8 cases per million doses: 11.5 per million doses in viral vector vaccine and 3.4 per million doses in mRNA vaccine.

Conclusions: OAEs can be observed shortly after the COVID-19 vaccination, and their category was different based on the types of vaccine. The information and incidence of OAE based on the type of vaccine can help monitor patients who were administered the COVID-19 vaccine.

References

Hashimoto Y, Yamana H, Iwagami M, Ono S, Takeuchi Y, Michihata N . Ocular Adverse Events after Coronavirus Disease 2019 mRNA Vaccination: Matched Cohort and Self-Controlled Case Series Studies Using a Large Database. Ophthalmology. 2022; 130(3):256-264. PMC: 9597516. DOI: 10.1016/j.ophtha.2022.10.017. View

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M . Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020; 369(6499):77-81. PMC: 7202686. DOI: 10.1126/science.abc1932. View

Singh R, Parmar U, Kahale F, Agarwal A, Tsui E . Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis. Ophthalmology. 2022; 130(2):179-186. PMC: 9428109. DOI: 10.1016/j.ophtha.2022.08.027. View

Ichhpujani P, Parmar U, Duggal S, Kumar S . COVID-19 Vaccine-Associated Ocular Adverse Effects: An Overview. Vaccines (Basel). 2022; 10(11). PMC: 9697513. DOI: 10.3390/vaccines10111879. View

Suresh P, Petchey W . ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Rep. 2021; 14(6). PMC: 8211078. DOI: 10.1136/bcr-2021-243931. View

Terpos E, Politou M, Ntanasis-Stathopoulos I, Karalis V, Merkouri E, Fotiou D . High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. Vaccines (Basel). 2021; 9(7). PMC: 8309977. DOI: 10.3390/vaccines9070712. View

Salah H, Mehta J . COVID-19 Vaccine and Myocarditis. Am J Cardiol. 2021; 157:146-148. PMC: 8272967. DOI: 10.1016/j.amjcard.2021.07.009. View

Greinacher A, Thiele T, Warkentin T, Weisser K, Kyrle P, Eichinger S . Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021; 384(22):2092-2101. PMC: 8095372. DOI: 10.1056/NEJMoa2104840. View

Hafeez M, Ikram M, Shafiq Z, Sarfraz A, Sarfraz Z, Jaiswal V . COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis. Clin Appl Thromb Hemost. 2021; 27:10760296211048815. PMC: 8552386. DOI: 10.1177/10760296211048815. View

10.

Roberts H, Wilkins M, Malik M, Talachi-Langroudi M, Myerscough J, Pellegrini M . A lack of an association between COVID-19 vaccination and corneal graft rejection: results of a large multi-country population based study. Eye (Lond). 2022; 37(11):2316-2319. PMC: 9734330. DOI: 10.1038/s41433-022-02341-7. View

11.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

12.

Palaiodimou L, Stefanou M, Katsanos A, Aguiar de Sousa D, Coutinho J, Lagiou P . Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines: A Systematic Review and Meta-analysis. Neurology. 2021; 97(21):e2136-e2147. DOI: 10.1212/WNL.0000000000012896. View

13.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

14.

Mucke V, Knop V, Mucke M, Ochsendorf F, Zeuzem S . First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report. BMC Infect Dis. 2021; 21(1):958. PMC: 8443965. DOI: 10.1186/s12879-021-06655-x. View

15.

Park H, Byun Y, Byeon S, Kim S, Kim Y, Lee C . Retinal Hemorrhage after SARS-CoV-2 Vaccination. J Clin Med. 2021; 10(23). PMC: 8658415. DOI: 10.3390/jcm10235705. View

16.

Althaus K, Marini I, Zlamal J, Pelzl L, Singh A, Haberle H . Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021; 137(8):1061-1071. PMC: 7791311. DOI: 10.1182/blood.2020008762. View

17.

Tomkins-Netzer O, Sar S, Barnett-Griness O, Friedman B, Shyriaieva H, Saliba W . Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis: A Population-Based Study. Ophthalmology. 2022; 129(10):1087-1095. PMC: 9132378. DOI: 10.1016/j.ophtha.2022.05.015. View

18.

Dorney I, Shaia J, Kaelber D, Talcott K, Singh R . Risk of New Retinal Vascular Occlusion After mRNA COVID-19 Vaccination Within Aggregated Electronic Health Record Data. JAMA Ophthalmol. 2023; 141(5):441-447. PMC: 10102921. DOI: 10.1001/jamaophthalmol.2023.0610. View

19.

Ng X, Betzler B, Testi I, Ho S, Tien M, Ngo W . Ocular Adverse Events After COVID-19 Vaccination. Ocul Immunol Inflamm. 2021; 29(6):1216-1224. PMC: 8477588. DOI: 10.1080/09273948.2021.1976221. View

20.

Martinez-Thompson J, Diehl N, Holmes J, Mohney B . Incidence, types, and lifetime risk of adult-onset strabismus. Ophthalmology. 2013; 121(4):877-82. PMC: 4321874. DOI: 10.1016/j.ophtha.2013.10.030. View